- Home
- OSUR vs ANNX Comparison
OSUR vs ANNX Comparison
Compare OSUR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- ANNX
- Stock Information
- Founded
- OSUR 2000
- ANNX 2011
- Country
- OSUR United States
- ANNX United States
- Employees
- OSUR N/A
- ANNX N/A
- Industry
- OSUR Medical/Dental Instruments
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- ANNX Health Care
- Exchange
- OSUR Nasdaq
- ANNX Nasdaq
- Market Cap
- OSUR 223.0M
- ANNX 252.3M
- IPO Year
- OSUR 1986
- ANNX 2020
- Fundamental
- Price
- OSUR $3.06
- ANNX $2.81
- Analyst Decision
- OSUR Hold
- ANNX Strong Buy
- Analyst Count
- OSUR 1
- ANNX 4
- Target Price
- OSUR $3.00
- ANNX $12.50
- AVG Volume (30 Days)
- OSUR 783.1K
- ANNX 1.4M
- Earning Date
- OSUR 08-05-2025
- ANNX 08-11-2025
- Dividend Yield
- OSUR N/A
- ANNX N/A
- EPS Growth
- OSUR N/A
- ANNX N/A
- EPS
- OSUR N/A
- ANNX N/A
- Revenue
- OSUR $161,626,000.00
- ANNX N/A
- Revenue This Year
- OSUR N/A
- ANNX N/A
- Revenue Next Year
- OSUR $6.20
- ANNX N/A
- P/E Ratio
- OSUR N/A
- ANNX N/A
- Revenue Growth
- OSUR N/A
- ANNX N/A
- 52 Week Low
- OSUR $2.36
- ANNX $1.29
- 52 Week High
- OSUR $4.92
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- OSUR 57.98
- ANNX 68.43
- Support Level
- OSUR $2.92
- ANNX $2.30
- Resistance Level
- OSUR $3.08
- ANNX $2.53
- Average True Range (ATR)
- OSUR 0.14
- ANNX 0.20
- MACD
- OSUR 0.01
- ANNX 0.00
- Stochastic Oscillator
- OSUR 84.85
- ANNX 76.71
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.